Inventor · disambiguated record
Andrew Scott
Also filed as: SCOTT ANDREW · SCOTT ANDREW M · SCOTT ANDREW MARK
17 granted patents·18 pending applications·154 citations·filing 2002–2023
91Inventor score
Files withJOHNS TERRANCE GRANT6LUDWIG INST CANCER RES6LUDWIG INST FOR CANCER RES LTD6DOW GLOBAL TECHNOLOGIES LLC3LACKMANN MARTIN3
Top patents by PatentIndex Score
35 records- 0195US7589180B2Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted Sep 15, 2009·70 cites·4 claims
- 0292US7767792B2Antibodies to EGF receptor epitope peptidesLUDWIG INST FOR CANCER RES LTD·Filed 2005·Granted Aug 3, 2010·32 cites·17 claims
- 0392US7381801B2Chimerized GM-CSF antibodiesLUDWIG INST CANCER RES·Filed 2003·Granted Jun 3, 2008·28 cites·3 claims
- 0488US8652473B2Antibodies to EGF receptor epitope peptides and uses thereofJOHNS TERRANCE GRANT·Filed 2010·Granted Feb 18, 2014·11 cites·20 claims
- 0584US9169329B2Antibodies directed to the receptor tyrosine kinase c-MetJOHNS TERRANCE GRANT·Filed 2011·Granted Oct 27, 2015·7 cites·20 claims
- 0684US2024117073A1Methods of treating neoplastic astrocytomaLUDWIG INST FOR CANCER RES LTD·Filed 2023·Application pending·0 cites
- 0779US7714113B2Fusion proteins of humanized g250 specific antibodies and uses thereofLUDWIG INST CANCER RES·Filed 2003·Granted May 11, 2010·4 cites·9 claims
- 0872US9023356B2Treatment method using EGFR antibodies and SRC inhibitors and related formulationsJOHNS TERRANCE GRANT·Filed 2008·Granted May 5, 2015·2 cites·14 claims
- 0971US2021032366A1Methods of treating neoplastic astrocytomaLUDWIG INST FOR CANCER RES LTD·Filed 2020·Application pending·0 cites
- 1068US7897743B2Humanized GM-CSF antibodiesLUDWIG INST CANCER RES·Filed 2008·Granted Mar 1, 2011·0 cites·12 claims
- 1164US2009220510A1Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2008·Application pending·0 cites
- 1261US2009259027A1Human GM-CSF antibodiesRENNER CHRISTOPH·Filed 2008·Application pending·0 cites
- 1361US2018057606A1Methods of treating meningiomaLUDWIG INST FOR CANCER RES LTD·Filed 2017·Application pending·0 cites
- 1461US2014322130A1Specific binding proteins and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2014·Application pending·0 cites
- 1560US9283276B2Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereofJOHNS TERRANCE GRANT·Filed 2008·Granted Mar 15, 2016·0 cites·18 claims
- 1660US2022275075A1Methods and compositions for pdgf-cc inhibitionPARACRINE THERAPEUTICS AB·Filed 2022·Application pending·0 cites
- 1758US9528034B2Cyanoacrylate compositionsHenkel IP & Holding GmbH·Filed 2015·Granted Dec 27, 2016·0 cites·12 claims
- 1855US2016046726A1Specific binding proteins and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2015·Application pending·0 cites
- 1954US12350288B2Inducing caspase activityDOW GLOBAL TECHNOLOGIES LLC·Filed 2020·Granted Jul 8, 2025·0 cites·9 claims
- 2054US8637016B2EphA3 antibodies for the treatment of solid tumorsLACKMANN MARTIN·Filed 2008·Granted Jan 28, 2014·0 cites·30 claims
- 2152US2012029172A1Humanized GM-CSF antibodiesRENNER CHRISTOPH·Filed 2011·Application pending·0 cites
- 2251US2025009917A1Macrocycle containing compounds and radiolabelled complexes thereof, as ligands in targeted radiotherapy applicationsUNIV MELBOURNE·Filed 2022·Application pending·0 cites
- 2351US2011313230A1Specific binding proteins and uses thereofJOHNS TERRANCE GRANT·Filed 2011·Application pending·0 cites
- 2450US11352420B2Methods and compositions for PDGF-CC inhibitionPARACRINE THERAPEUTICS AB·Filed 2017·Granted Jun 7, 2022·0 cites·2 claims
- 2545US12251399B2Inducing caspase activityDOW GLOBAL TECHNOLOGIES LLC·Filed 2020·Granted Mar 18, 2025·0 cites·6 claims
- 2645US12201647B2Inducing caspase activityDOW GLOBAL TECHNOLOGIES LLC·Filed 2020·Granted Jan 21, 2025·0 cites·13 claims
- 2745US2006140957A1Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasisLACKMANN MARTIN·Filed 2004·Application pending·0 cites
- 2844US2017335001A1Detection of EphA3 as a Marker of the Presence of a Solid TumorKALOBIOS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2942US11160873B2Anti-metalloprotease antibody for diagnosis and treatment of cancersUNIV MONASH·Filed 2018·Granted Nov 2, 2021·0 cites·18 claims
- 3042US2011293511A1Specific binding proteins and uses thereofJOHNS TERRANCE GRANT·Filed 2011·Application pending·0 cites
- 3141US2011318304A1Detection of epha3 as a marker of the presence of a solid tumorLACKMANN MARTIN·Filed 2011·Application pending·0 cites
- 3241US2008268459A1Anti-Lewis Y Anti-Idiotypic Antibodies and Uses ThereofWYETH LUDWIG INST FOR CANCER·Filed 2004·Application pending·0 cites
- 3338US10023653B2Anti-metalloprotease antibody for diagnosis and treatment of cancersUNIV MONASH·Filed 2015·Granted Jul 17, 2018·0 cites·5 claims
- 3437US2011076232A1Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2010·Application pending·0 cites
- 3534US2003103968A1Use of alpha specific antibody BIBH1 in the treatment of cancerFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrew Scott files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →